Replimune Group, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Replimune Group, Inc. (REPL) on August 9, 2026. The filing discloses the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares.
- Offering Price: $12.06 per share for common stock; $12.0599 per pre-funded warrant.
- Estimated Net Proceeds: Approximately $140.5 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co.
- Expected Closing Date: On or about August 11, 2026.
Material Changes and Transaction Terms
The filing represents a material capital event involving the issuance of new equity securities. The pre-funded warrants are exercisable immediately but are subject to a beneficial ownership limitation of 9.99% of outstanding shares immediately after exercise. Holders may adjust this limit with 61 days' prior notice. The offering is being made pursuant to a Shelf Registration Statement on Form S-3 filed in May 2025 and amended in November 2025.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding expected net proceeds and the closing date. The Company notes that actual results could differ materially due to risks detailed in its Form 10-K and 10-Q filings and the final prospectus supplement. No specific operational guidance or management commentary on future business performance is provided in this specific filing beyond the transaction details.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds upon completion of the offering.
- Review the final prospectus supplement for updated risk factors and use of proceeds.
- Monitor the impact of the new share issuance on existing shareholder dilution.
- Confirm the exercise terms and beneficial ownership limits of the pre-funded warrants.